Cambridge AI vaccine shows promise against bird flu

New shots beat old ones

A new bird flu vaccine developed using artificial intelligence has shown promising results in early animal trials. New findings from the University of Cambridge and its spinout company DIOSynVax show that every experimental animal receiving the AI-designed vaccine lived after being exposed to various bird flu strains. Only about half of those receiving conventional vaccines survived during these tests. A recent investigation appearing in Cell Reports Medicine demonstrated that the novel immunization fully shielded mice and ferrets from various genetic variants of avian influenza.

Study led by Heeney

Professor Jonathan Heeney from the University of Cambridge directed the research, while labs in Canada and Italy independently verified the vaccine's effectiveness through separate assessments. Every viral strain examined in this research has already been documented as capable of infecting people. Under the World Health Organization pandemic influenza preparedness programme, governments are now stockpiling vaccines intended for humans that target specific virus strains. Standard immunizations typically afford robust defense against particular strains yet might yield restricted immunity toward alternative variants.

Further human trials needed

Scientists stated that viruses are always evolving genetically, which requires regular vaccine revisions and raises expenses for state authorities. According to these results, using artificial intelligence in vaccine creation might enable new shots that defend against several viral strains at once. Nevertheless, scientists warned that additional research and clinical testing are required to confirm the vaccine's safety and efficacy in people.